Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. (Q39499342)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

prostate cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

7

object named as

Gabor Halmos

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Anton Stangelberger

1

object named as

Anton Stangelberger

1 reference

Europe PubMed Central

PubMed publication ID

8 February 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

author name string

Jozsef L Varga

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Benjamin Baker

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Marta Zarandi

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

27 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

72

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

555-565

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21796649%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

The development of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

New approaches to the therapy of various tumors based on peptide analogues

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antagonists of growth hormone-releasing hormone in oncology

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Clinical implications of p53 mutations

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Expression patterns of potential therapeutic targets in prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Modulation of gene expression by tumor-derived p53 mutants

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Targeting prostate cancer based on signal transduction and cell cycle pathways.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

The multiple battles fought by anti-apoptotic p21.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

p53 oncogene mutations in three human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Molecular characterization of human prostate carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288).

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21458

21 January 2018

Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

p53 Protein Accumulation and Gene Mutation in the Progression of Human Prostate Carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Ileal T-pouch as a urinary continent cutaneous diversion: clinical and urodynamic evaluation

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21(waf1/cip1)

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.21458

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39499342&oldid=2119264025"